Jump to main content

Fortune 09/29/2015

The Drug Price Conundrum: a Q&A with Memorial Sloan Kettering's Dr. Peter B. Bach

Drug prices have taken center stage since Turing Pharmaceuticals raised the price of its off-patent parasite-fighting drug Daraprim by over 5,000%, but the issue has been lingering for far longer than Turing has even existed.

Prices for brand-name drugs increased almost 15% over the past year alone, according to research firm Truveris.

Meanwhile, the costs of lifesaving specialty cancer drugs have increased by an average of 10% per year since 1995, even when adjusted for inflation, according to one recent study.

Read the full article here.

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Explore Our Research

Xeljanz, the FDA, and nine years of patient harm

Quantifying population-level adverse events in the near decade between when safety concerns were identified and FDA action

Drug Pricing Lab 05/31/2022

Atypical antipsychotics: Decades of use, unfathomable harms

Using attributable risk calculations to quantify how many premature deaths resulted from atypical antipsychotic use in the elderly

Drug Pricing Lab 05/31/2022

Medicare Part B Premium Dynamics Explained

The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.

Milliman 12/23/2021

Comparing Factors that Influence Pharmaceutical Pricing and Access in the…

Drug prices in the United States are some of the highest in the world, which has triggered several policy proposals aimed at adopting pricing strategies used by other countries.

Drug Pricing Lab 12/20/2021

Biosimilars in Medicare Part D: pricing dynamics and considerations

The Drug Pricing Lab engaged Milliman to prepare a report summarizing the pricing dynamics affecting utilization of biosimilars in the current Medicare Part D marketplace and under the proposed Part D benefit design in the Build Back Better Act.

This report was commissioned by the Drug Pricing Lab.

Milliman 12/14/2021

Evaluating Industry’s Drug Pricing Claims

A closer look at three of PhRMA’s most cited talking points.

Drug Pricing Lab 11/18/2021

Mapping conflict of interests: scoping review

A scoping review of the literature to identify all known ties between the medical product industry and the parties and activities in the healthcare ecosystem.

Drug Pricing Lab 11/03/2021

Production Plus Profit Pricing (P-quad) FAQ

Academic Literature

What A Waste! The National Academy Of Medicine’s Report On…

Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.

Health Affairs Blog 07/09/2021

Medicare Must Study Unproven, Expensive Alzheimer’s Drug

Medicare cannot indiscriminately cover the cost of Aduhelm for the treatment of Alzheimer's disease without first evaluating whether it truly works.

Bloomberg Opinion 06/15/2021

Academic Literature

Value-Based Management of Specialty Drugs: Practical Considerations and Implications for…

Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.

AJMC 05/13/2021

Trump's Drug-Pricing Ideas Would Cost Taxpayers a Bundle

Meanwhile, pharmaceutical companies would stand to make a lot more money.

Bloomberg Opinion 09/29/2020

Explore Our Research